Selvigaltin (GB1211), an orally available small molecule galectin-3 inhibitor designed as a cure for liver fibrosis and cirrhosis, was evaluated to assess the outcome of hepatic impairment on its pharmacokinetics and basic safety to handle regulatory needs. In detail, we used the vehicle control teams because the calibrator in Every https://1978336-95-691245.fare-blog.com/39639790/indicators-on-selvigaltin-galectin-3-inhibitor-you-should-know